Most cases taken on a “if you don’t win, you don’t pay” basis.
Not all lawyers are willing to take your case.
Find out how to collect the most money for your injuries!
Fill out the form on the right to have a lawyer contact you.
For faster service call 800-611-7080
Choosing the right lawyer for your case can be a life changing decision.
Choosing the wrong lawyer for your case can cost you millions.
We match injured clients with law firms experienced in their case types.
We match injured clients with law firms experienced in their case types.
Fill out the form on the right and we will have an experienced lawyer contact you.
For faster service call 800-611-7080

Actos Litigation

By admin | Published January 6, 2012
Actos Litigation Contact Page
1-800-611-7080

 

Actos Litigation: A good starting point is your primary care physician. He will generally have a number of specialists to whom he generally refers his urology patients. If the primary care physician has been working with these urologists, he should have an appreciation of their skills and temperament. However, this does not mean he is referring you necessarily to the best available urologist in your area. His choices may be limited by insurance or hospital networks. An excellent source of information would be nurses who work in the operating room, recovery room or on the surgical floor where the urologist does his surgery. Asking friends or other individuals who have had experience with the urologist can also prove useful. After a little digging, you can often quickly learn what type of reputation the urologist has in the community. Generally, if an established urologist has a “good reputation” this is an indication that he has pleased many individuals with his care.

Given the litigious society we live in, most physicians can face at least one malpractice lawsuit during their careers. In urology, two of the most common causes of litigation would be a surgical mishap leading to a complication, or failure to diagnose cancer in a timely fashion.

Medicine is based on science, but also is an “art.” Individuals do not walk into their physicians offices with a diagnosis and treatment plan always readily apparent. Even the best intentioned, thorough physician will make mistakes. Most of these errors do not result in harm. On occasion they do, and a law suit may follow. If a physician develops a good working relationship with a patient, these bad outcomes more often than not are acknowledged and accepted without legal entanglement. Competent, busy physicians may be dealing with a higher mix of complicated patients, leading to a higher number of potential suits. Physicians who have poor “bed side manner” may find themselves dealing with more suits. If a physician has an inordinate number of suits, “red flags” should go up, as competency may be an issue.

For more information on Actos Litigation follow us on our RSS Feeds.

Medical information is scrutinized in journals and reviewed at conferences. The newest treatment regimens for advanced cancer are explored in clinical trials to determine their efficacy and safety. It is only after they are proven that they become adopted as standard practice by most physicians. For the vast majority of individuals with bladder cancer, excellent, comprehensive treatment can be obtained at the local level. For those requiring more specialized care or for those unfortunate individuals with advanced cancer who desire experimental therapy via a clinical trial for their cancer, a referral to the appropriate center may be appropriate.

Given the monetary pressures in today’s medical practice, some physicians are over booked and cannot see the allotted number of patients scheduled without delays. The theory behind this schedule is the expectation that a number of patients will not show for their appointment, allowing the physician to stay true to the schedule and not fall behind.

However, sometimes all of the patients do show, and the physician is delayed. Even with a carefully thought out schedule, emergencies may arise and some visits unexpectedly take longer than scheduled. The physician wants to devote the time and attention required for each individual. After all, you also expect the same time and attention during your visit. Even the most conscientious physician may find himself running behind in a busy medical practice. This lateness should be recognized by the physician who will often acknowledge it with an apology. If you find it distressing to wait more than fifteen minutes (a reasonable time to wait), you should discuss your feelings with your physician, who often can arrange an appointment at the beginning of the schedule when he will almost be guaranteed to be on time.

Information from other sources on Actos Litigation

You may need a second opinion if you are not doing well and your physician is unable to provide satisfactory explanations and solutions. Occasionally, your urologist may recommend a second opinion if your problem is unusual or particularly complicated. Having a physician you can trust is mandatory when dealing with cancer. Don’t let anyone pressure you into a second opinion if you feel confident in your physician’s abilities. On the other hand, if you are uncomfortable with your progress or a treatment recommendation, if you are not satisfied with the explanations given to you, don’t hesitate to seek out a second opinion. Your urologist should not feel threatened by this request as he wants you to feel comfortable with the plan of action. Only by partnering with your physician can he be most effective.

Cancer unfortunately is a common disease affecting almost all animals. People are equally susceptible; approximately one in three will be afflicted at some time in their life. In this chapter, we will review basic information regarding the bladder, bladder cancer, and cancer in general, including what causes it and some parameters used to determine how serious it is. A bladder stores urine and expels it at a convenient time. The bladder is a very useful organ, (tissues working together to accomplish a function), but an individual can live a normal life without one, if required, by surgical creation of a substitute. Bladder cancer can vary from the non serious, low grade superficial type (approximately 70%), to the invasive, aggressive type that can spread and prove to be fatal (approximately 30%). 5% of bladder cancer is accounted for by squamous cell carcinoma. This cancer is usually secondary to long term inflammation or infection of the bladder. Even rarer is adenocarcinoma, which accounts for less than 2% of all bladder cancers. More than 90% of bladder cancers arise from the lining bladder cells called transitional cells. Bladder cancer is almost always transitional cell cancer. These cells are also present in the urethra (the body tube which drains the bladder), as well as the renal pelvis (inner lining of the kidneys), and the ureters (the body tube draining the kidneys).

Our use of the term or terms Actos Litigation is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Litigation visit our site often.

Posted in Actos Litigation | Tagged |

Gardasil Lawyer

By admin | Published January 5, 2012

More information on Gardasil Lawyer

Mini-Sentinel is a pilot project to inform the development of an active surveillance system, the Sentinel System, for monitoring the safety of FDA-regulated medical products. FDA’s Center for Biologics Evaluation and Research (CBER) is currently evaluating three different vaccines (RotaTeq, Rotarix and Gardasil) using the Mini-Sentinel system. The inclusion of these vaccines as the subject of a Mini-Sentinel safety evaluation does not mean that a causal association exists between the vaccine and the health outcome being investigated. These evaluations are being conducted to provide better information to help clarify potential safety concerns that have been reported by other surveillance systems and enable FDA to better assess any potential risk.

1. Intussusception after rotavirus vaccination. Intussusception is the most common form of bowel obstruction in infancy and has been closely monitored since the voluntary withdrawal of the first rotavirus vaccine: Rotashield. FDA carefully assessed the risk for intussusception in large clinical trials in more than 60,000 children prior to licensure for both of the currently available rotavirus vaccines (RotaTeq and Rotarix). No increased risk for intussusception was observed in these trials for either vaccine. However, several postmarketing studies from other countries have subsequently suggested a potential increased risk. (FDA is conducting a Mini-Sentinel safety assessment because intussusception is a very rare event and studies thus far have not been large enough to sufficiently evaluate this risk among children in the United States. Mini-Sentinel has the largest general population cohort for vaccine safety surveillance in the United States and FDA is conducting this investigation to better quantify the potential risk of intussusception among US children.

2. Venous thromboembolism (VTE) after human papillomavirus vaccine. Venous thromboembolism is a condition that involves blood clots that form in the deep veins of the body (deep vein thrombosis) or in the lungs (pulmonary embolism). VTE can result from a combination of hereditary and acquired risk factors, including hormonal contraception. FDA approved Gardasil in 2006 based on studies involving more than 21,000 males and females. No increased risk for VTE was identified in these studies. Post licensure surveillance in the Vaccine Safety Datalink identified no safety risks among eight health outcomes which were evaluated, but a non-statistically significant increased rate of VTE after Gardasil was reported.[3] However, all of the confirmed cases of VTE in this study had other risk factors present that might explain their blood clots. FDA is conducting this Mini-Sentinel safety assessment to evaluate VTE with improved control for these other risk factors.

Additional information from the FDA on Gardasil Lawyer:

The results of these two studies will be published and made publicly available upon completion. FDA will evaluate any new safety information from these assessments and will provide updates to healthcare providers and the public to ensure the safe use of vaccines. The Mini-Sentinel safety assessments are part of FDA’s efforts to enhance vaccine safety surveillance, communication, and protection of public health.

http://www.seedol.com

Posted in Actos Litigation | Tagged , |

Gardasil Lawyer

By admin | Published January 5, 2012

For Continued information on Gardasil Lawyer

 

More (12/21/11) on Gardasil Lawyer

 

The FDA has recently received inquiries regarding the presence of human papillomavirus (HPV) DNA fragments in Gardasil and is aware that information related to this issue is on the internet. A concern that the presence of these fragments could represent contamination of the vaccine arises from an unpublished report that recombinant HPV L1-specific DNA sequences were present in 13 vials of Gardasil from different lots.

The presence of DNA fragments is expected in Gardasil and not evidence of contamination. Based on the scientific information available to FDA, Gardasil continues to be

safe and effective, and its benefits continue to outweigh its risks.

 

More relevant Information for Gardasil Lawyer

Key Facts:

  • Gardasil does contain recombinant HPV L1-specific DNA fragments, but these are not contaminants. DNA encoding the HPV L1 gene is used in the vaccine manufacturing process to produce the virus-like particles that make up the vaccine. The presence of these DNA fragments is expected, is not a risk to vaccine recipients, and is not a safety factor. DNA is the “blueprint” for the majority of living organisms and carries the genetic instructions for how cells function and grow.
  • The vaccine manufacturing process is highly regulated under FDA’s current good manufacturing practice requirements, including inspections conducted by FDA of the manufacturing processes and facilities.
  • Since the early development of Gardasil, FDA and the manufacturer (Merck and Co., Inc.) have known that after purification of the vaccine, small quantities of residual recombinant HPV L1-specific DNA fragments remain in the vaccine. Gardasil does not contain DNA from other HPV genes or any full-length infectious HPV genomes.
  • As it does with all vaccines, FDA continues to monitor the safety of Gardasil. For example, FDA recently evaluated the results of a postmarketing study, which included 189,629 females ages 9 to 26 years, 51% of whom were 9 to 15 years of age to assess the risk for onset of new autoimmune diseases after vaccination with Gardasil. Examples of these types of diseases include juvenile rheumatoid arthritis, lupus, multiple sclerosis, etc. The results of this study showed that there is no elevated risk for onset of new autoimmune disease associated with the use of Gardasil.
  • FDA also continually reviews all reports of the Vaccine Adverse Event Reporting System after vaccination with Gardasil, and there is no evidence of unusual clinical patterns or high reporting rates of adverse events, including autoimmune diseases.

 

One of FDA’s highest priorities is the protection of public health through safe and effective vaccines. As it does with all vaccines, FDA will continue to monitor the safety of Gardasil.

 

For Continued Updates on Gardasil Lawyer

http://www.seedol.com

Posted in Actos Litigation | Tagged , |

Gardasil Lawyers

By admin | Published January 5, 2012

Continued information on Gardasil Lawyers

More (12/21/11) on Gardasil Lawyers

 

Mini-Sentinel is a pilot project to inform the development of an active surveillance system, the Sentinel System, for monitoring the safety of FDA-regulated medical products. FDA’s Center for Biologics Evaluation and Research (CBER) is currently evaluating three different vaccines (RotaTeq, Rotarix and Gardasil) using the Mini-Sentinel system. The inclusion of these vaccines as the subject of a Mini-Sentinel safety evaluation does not mean that a causal association exists between the vaccine and the health outcome being investigated. These evaluations are being conducted to provide better information to help clarify potential safety concerns that have been reported by other surveillance systems and enable FDA to better assess any potential risk.

1. Intussusception after rotavirus vaccination. Intussusception is the most common form of bowel obstruction in infancy and has been closely monitored since the voluntary withdrawal of the first rotavirus vaccine: Rotashield. FDA carefully assessed the risk for intussusception in large clinical trials in more than 60,000 children prior to licensure for both of the currently available rotavirus vaccines (RotaTeq and Rotarix). No increased risk for intussusception was observed in these trials for either vaccine. However, several postmarketing studies from other countries have subsequently suggested a potential increased risk. (FDA is conducting a Mini-Sentinel safety assessment because intussusception is a very rare event and studies thus far have not been large enough to sufficiently evaluate this risk among children in the United States. Mini-Sentinel has the largest general population cohort for vaccine safety surveillance in the United States and FDA is conducting this investigation to better quantify the potential risk of intussusception among US children.

2. Venous thromboembolism (VTE) after human papillomavirus vaccine. Venous thromboembolism is a condition that involves blood clots that form in the deep veins of the body (deep vein thrombosis) or in the lungs (pulmonary embolism). VTE can result from a combination of hereditary and acquired risk factors, including hormonal contraception. FDA approved Gardasil in 2006 based on studies involving more than 21,000 males and females. No increased risk for VTE was identified in these studies. Post licensure surveillance in the Vaccine Safety Datalink identified no safety risks among eight health outcomes which were evaluated, but a non-statistically significant increased rate of VTE after Gardasil was reported.[3] However, all of the confirmed cases of VTE in this study had other risk factors present that might explain their blood clots. FDA is conducting this Mini-Sentinel safety assessment to evaluate VTE with improved control for these other risk factors.

Additional information from the FDA on Gardasil Lawyers

The results of these two studies will be published and made publicly available upon completion. FDA will evaluate any new safety information from these assessments and will provide updates to healthcare providers and the public to ensure the safe use of vaccines. The Mini-Sentinel safety assessments are part of FDA’s efforts to enhance vaccine safety surveillance, communication, and protection of public health.

http://www.seedol.com

Posted in Actos Litigation | Tagged , |

Gardasil Lawyers

By admin | Published January 5, 2012

For Continued information on Gardasil Lawyers

More (12/21/11) on Gardasil Lawyers:

The FDA has recently received inquiries regarding the presence of human papillomavirus (HPV) DNA fragments in Gardasil and is aware that information related to this issue is on the internet. A concern that the presence of these fragments could represent contamination of the vaccine arises from an unpublished report that recombinant HPV L1-specific DNA sequences were present in 13 vials of Gardasil from different lots.

The presence of DNA fragments is expected in Gardasil and not evidence of contamination. Based on the scientific information available to FDA, Gardasil continues to be

safe and effective, and its benefits continue to outweigh its risks.

More relevant Information for Gardasil Lawyers

Key Facts:

• Gardasil does contain recombinant HPV L1-specific DNA fragments, but these are not contaminants. DNA encoding the HPV L1 gene is used in the vaccine manufacturing process to produce the virus-like particles that make up the vaccine. The presence of these DNA fragments is expected, is not a risk to vaccine recipients, and is not a safety factor. DNA is the “blueprint” for the majority of living organisms and carries the genetic instructions for how cells function and grow.

• The vaccine manufacturing process is highly regulated under FDA’s current good manufacturing practice requirements, including inspections conducted by FDA of the manufacturing processes and facilities.

• Since the early development of Gardasil, FDA and the manufacturer (Merck and Co., Inc.) have known that after purification of the vaccine, small quantities of residual recombinant HPV L1-specific DNA fragments remain in the vaccine. Gardasil does not contain DNA from other HPV genes or any full-length infectious HPV genomes.

• As it does with all vaccines, FDA continues to monitor the safety of Gardasil. For example, FDA recently evaluated the results of a postmarketing study, which included 189,629 females ages 9 to 26 years, 51% of whom were 9 to 15 years of age to assess the risk for onset of new autoimmune diseases after vaccination with Gardasil. Examples of these types of diseases include juvenile rheumatoid arthritis, lupus, multiple sclerosis, etc. The results of this study showed that there is no elevated risk for onset of new autoimmune disease associated with the use of Gardasil.

• FDA also continually reviews all reports of the Vaccine Adverse Event Reporting System after vaccination with Gardasil, and there is no evidence of unusual clinical patterns or high reporting rates of adverse events, including autoimmune diseases.

One of FDA’s highest priorities is the protection of public health through safe and effective vaccines. As it does with all vaccines, FDA will continue to monitor the safety of Gardasil.

For Continued Updates on Gardasil Lawyers

http://www.seedol.com

Posted in Actos Litigation | Tagged , |

Actos Lawsuit

By admin | Published January 5, 2012

Actos Lawsuit: Phase I trials study how to administer a new drug or treat­ment and how much of the drug or treatment can be safely tolerated. The drugs or treatment in a phase I trial have been extensively tested in a lab and in animal studies, but not in humans. If a drug is being rested, researchers may start by giving a very low dose of the drug to those participating in the trial, then increase it gradually to derermine when side effects appear and what dosage is tolerable, yet effec­tive. Phase I trials usually enroll a small number of people at a limited number of locations. In general, they are the least likely to be of direct personal benefit to a patient, as the drugs are less well known, but occasionally they can lead to significant tumor shrinkage with side effects well within the tolerable range.

Phase II trials take the studies a step farther. From the phase I results, researchers know what dosage to give with a good margin of safety; in phase II they are ready to test whether the drug really works as well as anticipated. They carefully monitor patients in the study for side effects and observe closely how the drug affects the cancer. A phase II study usually targets a particular disease or type of cancer and includes fewer than 100 people.

Phase III trials involve large groups of people across a broad geographical area. A random process determines which indi­viduals will receive the drug being tested and which ones will receive standard treatment. The idea is to compare accurately whether the new treatment is better than the old treatment and whether there are different patterns of side effects and survival. The results are monitored closely, and if one treat­ment is observed to be significantly more effective than the other, the trial is stopped. Sometimes a phase III trial will find that the new treatment is not better than the standard, in which case the new treatment is usually dropped from the list. Studies are randomized—patients are chosen randomly for the new and standard treatments—to avoid introducing biases into the study. For example, without randomization, there might be an inadvertent tendency to choose younger and stronger patients for the new agent and older patients with other medical problems for the established treatment. This might make the new treatment appear to be better than the established treatment when, in fact, the differences were attributable only to the type of patient receiving each type of treatment. In some cases, where the benefits of a new drug are really uncertain, and it is not clear whether the new drug is better than no treatment at all, a phase III trial will compare the new drug to a placebo (an inactive agent). This is done to exclude the possibility of patients experiencing perceived benefit just because they are receiving treatment itself, rather than because the drug is actually reducing the cancer. As surprising as it seems, this effect (known as the placebo effect) really does occur occasionally. Doctors are required by law to inform patients if they are using a pla­cebo in such a trial.

For more information on Actos Lawsuit follow us on our RSS Feeds.

A document called an informed consentWiW help you sort through your questions and concerns. The form, which you sign, includes a disclosure statement from the researcher describing the protocol, who is conducting the trial, what tests will be made and how, the possible risks and the pos­sible benefits to you, and what side effects are anticipated. Informed consent gives you information you need to make a decision about participating in a clinical trial. An informed consent states that you agree to participate in the clinical trial and requires your signature.

Signing an informed consent form does not mean that you are legally bound in any way to remain in the clinical trial. You may drop out at any time. Before the trial starts, after it’s under way, during the follow-up period—anytime. Informed consent doesn’t end once the clinical trial has begun. Researchers are obligated to tell you if they find new side effects, benefits, or risks to participating in the study.

You have decided to participate in a phase III clinical trial in which a new drug is being tested by a research team. Who pays for it? Your usual care costs—those you would incur whether you are enrolled in a trial or not—are usually covered by your insurance plan or Medicare. But the extra care costs that are incurred by your par­ticipation in a clinical trial may not be covered. Often if a drug is being tested, it is provided to trial participants free of charge. But you may have a side effect, such as nausea, and require an antinausea prescription to address the com­plaint. Your insurance company may view the antinausea medication as an extra care cost. The clinical trial may or may not pay for the antinausea drugs or other office visits or tests specifically required as part of your being in the trial. Sometimes federal funding or grant programs help pay the costs; sometimes they don’t.

Information from other sources on Actos Lawsuit

Sadly, your insurance company may or may not agree to pay costs for expenses associated with the clinical trials. Some insurance companies consider such treatment experimental and, as such, refuse to pay. Before you agree to participate in a study, contact your insurance company to determine what your plan covers. Some states have passed legislation requir­ing insurance companies to cover the costs to patients of clin­ical trials. Federal health insurance, for the most part, covers clinical trials. Medicare does, for example, and so does healch insurance through the Department of Veterans Affairs and the Department of Defense. Things change, however, and you should double-check your coverage before going ahead with a clinical trial. If your insurance company does not cover clinical trial expenses and you want to participate, ask someone from your medical team or the clinical trial team to contact a representative from your insurance company. Sometimes after claims representatives review the clinical trial proto­col, they will approve payment. Also, the National Cancer Institute is working with many health-insurance and man- aged-care providers to find answers to the question of how to provide coverage for clinical trial participation.

After a clinical trial is over, the results are often pub­lished in medical magazines or scientific journals. Once a new drug or treatment has been deemed effective and safe, it becomes standard practice; this means that doctors accept and use the drug or treatment while providing everyday medical care.

Our use of the term or terms Actos Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Lawsuit visit our site often.

http://www.seedol.com

Posted in Actos Litigation | Tagged , |

Actos Lawsuit

By admin | Published January 5, 2012

Actos Lawsuit:  The bladder contains a number of layers, with muscle making up the deep layers and the bladder lining constituting the top layers. Up to 70 percent of bladder tumors are non-muscle-invasive at the time of initial presentation and may not represent life threatening disease. However, approximately 50-90 percent of noninvasive cancers will recur within 5 years of diagnosis and initial treatment. The likelihood of recurrence increases for patients who have high-grade tumors, large tumors, multiple tumors, flat tumors (versus tumors that grow on a stalk), or tumors that appear to invade small vessels that transport blood or lymphatic fluid. For that reason patients who have bladder cancer are monitored very closely and on a regular basis.

For more information on Actos Lawsuit follow us on our RSS Feeds.

For many patients, knowing that bladder cancer is likely to recur can be associated with great anxiety. However, most of these recurrences can be managed with further trans­urethral surgery (resection of the tumors via cystoscope) or intravesical chemotherapy (medication placed inside the bladder) such as mitomycin C or bacillus Calmette-Guerin (BCG) therapy. For patients with low-grade (less aggressive) disease, 5-10 percent will progress to worse (or invasive) disease when they recur. For patients with high-grade bladder cancer (the more aggressive type), 15-50 percent will progress to invasive disease and 10-25 percent will die of bladder cancer. For this reason it is of the utmost importance for patients with high-grade bladder cancer to be monitored very closely.

Information from other sources on Actos Lawsuit

Most urologists check urine cytology and perform flexible cystoscopy 3 months after the fteatment for an initial diagnosis of bladder cancer. The timing of the initial check and subsequent follow-up depends on a number of factors. Intervals are usually 3-6 months and vary depending on whether the patient has low- or high-grade bladder cancer, if they received intravesical treatment, and the level of concern about recurrence based on the patient’s risk factors and appearance of the first tumor. In general, patients with low-grade tumors are watched every 3-6 months for several years after initial diagnosis. Patients with high-grade tumors are followed with cytology and cystoscopy every 3 months for 2 years, then every 6 months for 2 years, and then annually thereafter is typically recommended. It is also suggested that the upper urinary tract (kidneys and ureters) are imaged (by x-ray, CT, or MRI) every 1-2 years to ensure that the tumors do not recur elsewhere in the urinary tract (outside of the bladder).

If chemotherapy was used first, BCG should be used as the second agent. If BCG was used initially, a second course of BCG can be repeated or BCG + interferon can be used as intravesical therapy. However, approximately So percent of patients who receive two courses of intravesical treatment will not have their bladder cancer controlled by medication alone. Therefore if a patient continues to recur despite continued resections and intravesical treatments, especially if they have high-grade disease, the risk of invasive disease continues to rise and they should consider cystectomy, which is surgical removal of the bladder. If they are unable or do not wish to undergo surgery, there are alternative therapies, including chemotherapy or radiation therapy These therapies do not often control cancer as well as surgical removal of the bladder. If a patient recurs and the cancer has spread outside of the bladder, either by invading odier organs in the pelvis or spreading to lymph nodes, there remain effective treatments to control the cancer. Options include surgery (cystectomy) in combina­tion with chemotherapy and/or radiation.

Our use of the term or terms Actos Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Lawsuit visit our site often.

http://www.seedol.com

Posted in Actos Litigation | Tagged , |

Actos Lawsuit

By admin | Published January 5, 2012

Actos Lawsuit: A clinical trial may include fewer than 100 people moni­tored at just one or two locations, or it can involve thou­sands of people monitored by many doctors, nurses, data collectors, and other researchers at diverse locations such as doctors’ offices, hospitals, clinics, or medical centers. Clinical trials are sponsored by government agencies such as the National Cancer Institute, as well as medical institutions, individual doctors or other medical personnel, medical foundations, and drug companies or companies that manufacture diagnostic testing equipment. You may be alarmed if your doctor suggests the possi­bility of participating in a clinical trial. Does it mean that you have no hope? What should you do? How should you respond?

It is important not to dismiss the idea out of hand. The words experimental, research, and human volunteer can be upsetting, particularly at a time when you are dealing with the emotional issues surrounding a diagnosis of advanced cancer. But treatments in clinical trials can often be highly beneficial to the patients who volunteer. You and your loved ones should talk with your medical team members about the clinical trial they are recommending and why it may benefit you. Noteworthy to many patients is that several studies have documented that patients who participate in clinical trials have better outcomes than those found in the community at large. However, this also may also be due to the types of patients who agree to participate in trials.

For more information on Actos Lawsuit follow us on our RSS Feeds.

Does referral to a clinical trial mean that there is no hope of your surviving this illness? Not at all! There is always hope of survival, and any doctor can tell you about people who have responded positively to treatment and not only sur­vived, but thrived. Participating in a clinical trial doesn’t mean that you wont continue to receive medical treatment; you will, and since the trial is a voluntary process, you have the right to stop participating in the trial at any time. As with any aspect of your treatment plan, you’ make the decision about whether to proceed. Don’t feel pressured to participate in a trial if it doesn’t feel right for you, but do give it objective thought and consideration.

As with any treatment, you should ask about possible risks, benefits, and side effects, how the treatment works, and what results doctors expect from the study. You will want to know who is conducting the clinical trial and what kind of oversight is in place. Also ask what is expected of you. Where will you go for the treatments? How often will you go? Are there more tests or office visits than you might have with standard treatment? Who administers the treat­ments and how are the results measured? Do you have to report regularly to the people who are conducting the trial? Who pays for it all? Will there be extra costs to you as a result of your participation? Will the team conducting the trial (or the doctors involved) stand to benefit personally from the results of the trial or its conduct?

Information from other sources on Actos Lawsuit

There are many kinds of clinical trials. Some test preven­tion, such as whether vitamin C prevents colds. Some test whether particular screening tests, such as mammograms for breast cancer, are effective. The clinical trials your team is likely to mention are treatment trials, whereby a new drug, a new treatment, or even a new way of applying a standard treatment will be examined and tested. Each treatment trial will have a very detailed and spe­cific plan called a protocol. Think of a protocol as a recipe or instructions that describe what will be done in the trial, why the trial is necessary, who is eligible to participate, and how it will be conducted. Any doctor or researcher who takes part in die trial uses the trial’s protocol to ensure consistent results and to make sure that the new drug or treatment is given properly and with maximum safety.

Within treatment trials, there are four categories, or phases. You should ask the members of your medical team which phase of clinical trial they are recommending to you and find out specific details about the trial, such as the num­ber of people involved, where the testing is being done, what benefits or drawbacks are expected for you personally, and how long the trial is expected to last.

Our use of the term or terms Actos Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Lawsuit visit our site often.

http://www.seedol.com

Posted in Actos Litigation | Tagged , |

Actos Class Action Lawsuit

By admin | Published January 5, 2012

Actos Class Action Lawsuit: When speaking with your doctor and other team members, be as clear as you can be when it comes to how much you really want to know. Some patients want every detail, whereas others hardly want any information. Your cancer should not seem like an obligation to go to graduate school, but you should feel infonned to your satisfaction. The amount of information is very personal, and you should make it known how much you really want to know.

Partner with your caregivers wheneveryou can. Ifsomething does not make sense to you, there is a reasonable chance that it does not make sense at all. Much of medicine is vocabulary, and learning the words that your team uses to communicate with each other will help you communicate with them as well. Does your doctor remember that you are allergic to penicillin? That you have a knee replacement? That you require antibiotics for a heart murmur before a procedure? Sure, but most professionals will be pleased if you help them remember these special details about you drat affect your care.

For more information on Actos Class Action Lawsuit follow us on our RSS Feeds.

Talking to your boss, coworker, and friends is tricky and very personal. There is no rule on how to handle this part of your life. In most cases, you will want to let people at work know your diagnosis if it will significantly impact on your job. Most workplaces have clear-cut rules about this; in addition, make sure you are aware of the details regarding the Family Medical Leave Act so you and your family members can take advantage of this when appropriate. Hospitals have social workers to help you if assistance is needed. What you discuss with your healthcare team is private and protected by HIPPA (the Health Information Privacy and Portability Act). If you would like information shared with family or others in your circle, you must officially notify your doctor in writing. Most offices have a simple form you can fill out to facilitate this process.

Information from other sources on Actos Class Action Lawsuit

Discussing your condition with your parents or your children is an emotional matter. These are people who love you and may actually depend on you, so they are interested in the success of your battle with bladder cancer. Cancer is a frightening concept, so the more calmly you can explain your situation, the more likely they will be able to provide you with support that is not compromised by the fear of the unknown. Teach them what you know, inform them of how they can obtain more information, and let them know you are getting the “best care. Adult children are in some ways the hardest to reassure. These grown-up kids, who may have kids of their own, look at you with a mixture of adult concern and childlike fear. You may want to ask your doctor to speak to them directiy if you believe you are unable to satisfy their curiosity about your course of care. Your children may also push you to seek additional opin­ions, which is fine. We suggest you listen but don’t let them push you around. This is your problem and you are the one who needs to feel comfortable with your healthcare team.

Our use of the term or terms Actos Class Action Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos Class Action Lawsuit visit our site often.

http://www.seedol.com

Posted in Actos Litigation | Tagged , |

Multaq Liver Failure

By admin | Published January 5, 2012

Multaq Liver Failure : The most common type of benign liver tumor, hemangiomas are estimated to occur in up to 20 percent of the population; about one-tenth of affected individuals-—more women than men—will have more than one. Hemangiomas also occur in the brain, lungs, or skin, and they crop up at any age.

Hemangiomas almost always remain small, and because they usually cause no symptoms, most people with these masses are not aware they are diere. Occasionally, the hemangioma will grow larger than a few centimeters and begin to cause pain in the upper right quadrant of the abdomen. If the hemangioma continues to expand, the tumor can begin to bleed, sometimes forming blood clots within itself and causing pain.

Hemangiomas rarely bleed into the abdominal cavity, but it does happen—and this is an extremely serious and painful event that calls for emergency surgery.

Typically, hemangiomas are discovered during a sonogram or CT scan for an unrelated disorder. If the mass is larger than two and one-half centimeters, a tagged red blood cell (RBC) scan—a test that dyes the blood with a radioactive metallic element called a tracer—may be ordered. The RBC scan is a lengthy test; it takes about two hours for the tracer to accumulate in the hemangioma before the diagnosis is confirmed.

If the hemangioma is greatly enlarged (more than 10 to 15 centimeters) or causes pain, surgical removal may be required. Otherwise, hemangiomas generally are left alone and should nor undergo needle biopsy.

 

More information on Multaq Liver Failure

Hepatic adenoma. Much less common than hemangiomas are hepatic adenomas, benign tumors usually found in women of childbearing age who have taken birth-control pills for at least five years or who have had several pregnancies. Researchers believe these tumors are caused by increased amounts of estrogen. The good news is that the number of hepatic adenomas is declining as the quanitity of estrogen in birth-control pills is decreasing.

About half of hepatic adenoma patients complain of pain in the right upper quadrant of their abdomens, but many others detect no symptoms at all until the tumor ruptures, a serious and painftd emergency requiring immediate surgery. For still other patients, the tumor is often found during routine physical exams or when diagnostic studies are made for an unrelated disorder. Tumors can be located with CT scans and MRIs, but only a liver biopsy confirms the diagnosis.

Although hepatic adenomas are benign, occasionally they lead to liver cancer, so treatment is usually indicated. The least invasive and most successful form of treatment is to stop the use of any prescriptions that contain estrogen. If the tumor persists, surgery is usually the next step.

Doctors advise prospective mothers to defer pregnancy until the adenoma has been successfully treated because a pregnant womans hormone fluctuations can cause the tumor to grow and rupture. Once the hepatic adenoma is gone, however, it is safe to go ahead with a pregnancy.

Information from other sources on Multaq Liver Failure

Focal nodular hyperplasia (FNH). A benign tumor more common to women is focal nodular hyperplasia (FNH), a mass of liver cells that multiply around a malformed hepatic artery. Most women experience no symptoms unless the tumor is greatly enlarged, at which point the patient may notice abdominal pain or a mass felt with the finsers.

Focal nodular hyperplasia is less worrisome than some other benign tumors because it rarely ruptures and never progresses to liver cancer. Typically the tumor is discovered during a scan for an unrelated problem. The only treatment is to discontinue estrogen- containing medications because hormone imbalance, while not a proven cause of FNH, is thought to contribute to the tumor’s growth. If the FNH is causing discomfort, the doctor might recommend surgical removal.

Like other kinds of cysts, a liver cyst is a sac that contains fluid. Cysts are common and are sometimes found on the liver at birth, and usually appear in the liver’s right lobe. Like most benign liver tumors, solitary liver cysts are found more often in women than in men. Usually, cysts cause no symptoms and are detected during exams for other conditions. If they grow larger than five centimeters, they can cause pain, and very occasionally the)” will bleed or become infected. In such instances, symptoms do appear, including pain, fever, or elevated liver enzymes. Those cysts are likely to be treated with ablation therapy-—-a procedure in which alcohol or doxycycline (an antibiotic) is injected into the cyst, causing it to shrink and self-destruct, thereby ending the symptoms. If the cyst returns, it can be removed with surgery. Unless the cyst causes symptoms, no treatment is prescribed.

Our use of the term or terms Multaq Liver Failure is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq Liver Failure visit our site often.

http://www.seedol.com

Posted in Actos Litigation | Tagged , |

Cervical Cancer Shot

By admin | Published January 4, 2012

More information on Cervical Cancer Shot:

Mini-Sentinel is a pilot project to inform the development of an active surveillance system, the Sentinel System, for monitoring the safety of FDA-regulated medical products. FDA’s Center for Biologics Evaluation and Research (CBER) is currently evaluating three different vaccines (RotaTeq, Rotarix and Gardasil) using the Mini-Sentinel system. The inclusion of these vaccines as the subject of a Mini-Sentinel safety evaluation does not mean that a causal association exists between the vaccine and the health outcome being investigated. These evaluations are being conducted to provide better information to help clarify potential safety concerns that have been reported by other surveillance systems and enable FDA to better assess any potential risk.

  1. Intussusception after rotavirus vaccination. Intussusception is the most common form of bowel obstruction in infancy and has been closely monitored since the voluntary withdrawal of the first rotavirus vaccine: Rotashield. FDA carefully assessed the risk for intussusception in large clinical trials in more than 60,000 children prior to licensure for both of the currently available rotavirus vaccines (RotaTeq and Rotarix). No increased risk for intussusception was observed in these trials for either vaccine. However, several postmarketing studies from other countries have subsequently suggested a potential increased risk. (FDA is conducting a Mini-Sentinel safety assessment because intussusception is a very rare event and studies thus far have not been large enough to sufficiently evaluate this risk among children in the United States. Mini-Sentinel has the largest general population cohort for vaccine safety surveillance in the United States and FDA is conducting this investigation to better quantify the potential risk of intussusception among US children.
  2. Venous thromboembolism (VTE) after human papillomavirus vaccine. Venous thromboembolism is a condition that involves blood clots that form in the deep veins of the body (deep vein thrombosis) or in the lungs (pulmonary embolism). VTE can result from a combination of hereditary and acquired risk factors, including hormonal contraception. FDA approved Gardasil in 2006 based on studies involving more than 21,000 males and females. No increased risk for VTE was identified in these studies. Post licensure surveillance in the Vaccine Safety Datalink identified no safety risks among eight health outcomes which were evaluated, but a non-statistically significant increased rate of VTE after Gardasil was reported.[3] However, all of the confirmed cases of VTE in this study had other risk factors present that might explain their blood clots. FDA is conducting this Mini-Sentinel safety assessment to evaluate VTE with improved control for these other risk factors.

Additional information from the FDA on Cervical Cancer Shot:

 

The results of these two studies will be published and made publicly available upon completion. FDA will evaluate any new safety information from these assessments and will provide updates to healthcare providers and the public to ensure the safe use of vaccines. The Mini-Sentinel safety assessments are part of FDA’s efforts to enhance vaccine safety surveillance, communication, and protection of public health.

 

 

http://www.seedol.com

Posted in Actos Litigation | Tagged , |

Cervical Cancer Shot

By admin | Published January 4, 2012

More (12/20/11) on Cervical Cancer Shot:

The FDA has recently received inquiries regarding the presence of human papillomavirus (HPV) DNA fragments in Gardasil and is aware that information related to this issue is on the internet. A concern that the presence of these fragments could represent contamination of the vaccine arises from an unpublished report that recombinant HPV L1-specific DNA sequences were present in 13 vials of Gardasil from different lots.

The presence of DNA fragments is expected in Gardasil and not evidence of contamination. Based on the scientific information available to FDA, Gardasil continues to be

safe and effective, and its benefits continue to outweigh its risks.

More relevant Information for Cervical Cancer Shot:

Key Facts:

• Gardasil does contain recombinant HPV L1-specific DNA fragments, but these are not contaminants. DNA encoding the HPV L1 gene is used in the vaccine manufacturing process to produce the virus-like particles that make up the vaccine. The presence of these DNA fragments is expected, is not a risk to vaccine recipients, and is not a safety factor. DNA is the “blueprint” for the majority of living organisms and carries the genetic instructions for how cells function and grow. http://www.cervicalcancershot.com/cervical-cancer-shot/

More (12/20/11) on Cervical Cancer Shot:

The FDA has recently received inquiries regarding the presence of human papillomavirus (HPV) DNA fragments in Gardasil and is aware that information related to this issue is on the internet. A concern that the presence of these fragments could represent contamination of the vaccine arises from an unpublished report that recombinant HPV L1-specific DNA sequences were present in 13 vials of Gardasil from different lots.

The presence of DNA fragments is expected in Gardasil and not evidence of contamination. Based on the scientific information available to FDA, Gardasil continues to be

safe and effective, and its benefits continue to outweigh its risks.

More relevant Information for Cervical Cancer Shot:

Key Facts:

• Gardasil does contain recombinant HPV L1-specific DNA fragments, but these are not contaminants. DNA encoding the HPV L1 gene is used in the vaccine manufacturing process to produce the virus-like particles that make up the vaccine. The presence of these DNA fragments is expected, is not a risk to vaccine recipients, and is not a safety factor. DNA is the “blueprint” for the majority of living organisms and carries the genetic instructions for how cells function and grow.

• The vaccine manufacturing process is highly regulated under FDA’s current good manufacturing practice requirements, including inspections conducted by FDA of the manufacturing processes and facilities.

• Since the early development of Gardasil, FDA and the manufacturer (Merck and Co., Inc.) have known that after purification of the vaccine, small quantities of residual recombinant HPV L1-specific DNA fragments remain in the vaccine. Gardasil does not contain DNA from other HPV genes or any full-length infectious HPV genomes.

• As it does with all vaccines, FDA continues to monitor the safety of Gardasil. For example, FDA recently evaluated the results of a postmarketing study, which included 189,629 females ages 9 to 26 years, 51% of whom were 9 to 15 years of age to assess the risk for onset of new autoimmune diseases after vaccination with Gardasil. Examples of these types of diseases include juvenile rheumatoid arthritis, lupus, multiple sclerosis, etc. The results of this study showed that there is no elevated risk for onset of new autoimmune disease associated with the use of Gardasil.

• FDA also continually reviews all reports of the Vaccine Adverse Event Reporting System after vaccination with Gardasil, and there is no evidence of unusual clinical patterns or high reporting rates of adverse events, including autoimmune diseases.

One of FDA’s highest priorities is the protection of public health through safe and effective vaccines. As it does with all vaccines, FDA will continue to monitor the safety of Gardasil.

 

http://www.seedol.com

Posted in Actos Litigation | Tagged , |

Actos Attorneys

By admin | Published January 4, 2012

Actos Attorneys 12/29/2011:  When facing the prospects of chemotherapy, it is essential to have an oncologist who can inform you fully of the potential probable effectiveness of the chemotherapy being offered. Just as importantly, the toxicities of the chemotherapy must be fully reviewed. Of course, there are no absolutes when reviewing the potential for success and failure. Each individual’s cancer is unique. Some respond better than others to chemotherapy. General statistics regarding disease regression and remission are available. Absolute numbers for the individual are not.

After several courses of chemotherapy, an assessment of your clinical progress will be made. This will generally require a study such as a CAT scan, to check the response of the cancer to the chemotherapy. If progress is being made and the individual is tolerating the chemotherapy, a decision is then made to continue the chemotherapy to completion. If on the other hand, the cancer is not responding or the individual is not tolerating the therapy, a decision can be made to stop further chemotherapy, alter the present regimen, or try a different course of chemotherapy.

For more information on Actos Attorneys follow us on our RSS Feeds.

Our use of the Lawsuit, Lawyers is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos. Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com

Posted in Actos Litigation | Tagged , |

Actos Attorneys

By admin | Published January 4, 2012

Actos Attorneys 12/29/2011:  The neurovascular bundles which run adjacent and adherent to the prostate can be pushed aside as the bladder and prostate are removed. This is more technically difficult compared to the standard non-nerve sparing approach. Sparing the nerves is not always possible even with the best effort. If the individual has questionable erections prior to the surgery, a nerve sparing procedure rarely leads to preservation of erections and therefore is not warranted. Extensive bladder cancer may encroach on the prostate, making a nerve sparing procedure extremely difficult if not impossible.

There are multiple factors which must be considered. Generally younger patients, those in better overall health, and those with excellent preoperative erections can expect a more rapid return of erectile activity if the nerve sparing approach is successful. Even with meticulous nerve sparing, some nerve injury, either temporary or permanent may occur. The extent of the injury will determine how quickly erections may return. Erections may start returning in as little as two to three months, or may gradually return over a period of a year, or may not return at all. A number of other options are available if oral medications are ineffective, if the individual does not tolerate the medications, or is not a candidate for taking them.

For more information on Actos Attorneys follow us on our RSS Feeds.

Our use of the Terms Attorney is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Acts. Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

 

http://www.seedol.com

Posted in Actos Litigation | Tagged , |

Multaq Lawsuit

By admin | Published January 4, 2012

Multaq Lawsuit : Amoxici 11 i n-cl avu 1 an ate (Augmentin). This antibiotic has been used clinically for more than two decades to treat numerous types of bacterial infections. It has also been implicated as one of the most common causes of drug-induced liver injury worldwide.

Amoxicillin-clavulanate-related DILI may develop during or shortly after completion of the course of treatment, and most drug- induced liver injuries are mild and self-limited, even for patients who develop jaundice. There have been very rare instances, however, in which a patient develops severe hepatotoxicity and requires a liver transplant.

Isoniazid or INH (Nydrazid). This medication is used to treat tuberculosis, and anyone taking it should be concerned about hep- atotoxicity. As many as 10 to 20 percent of patients taking INH will develop a mild degree of AST/ALT elevation. Typically, these elevations are noted at the beginning of treatment, since doctors keep a watchful eye for liver toxicity. Most patients who develop mild liver-enzyme elevations will adapt to the medication and the enzymes will return to normal even when patients continue to take the medication. It is estimated that only about 1 percent of patients over age 50 will develop significant liver injury while undergoing treatment, especially if this treatment is combined with other medications to treat tuberculosis, such as rifampin or pyrazinamide. Other variables that may increase a patients risk of developing drug-induced liver injury include alcohol abuse, chronic hepatitis B, chronic hepatitis C, or HIV infection.

 

More information on Multaq Lawsuit:

Minocycline (Minocin or Dynacin). Thousands of people across the United States take minocycline on a daily basis to treat acne. Most people take this medication without any problem or experience of toxicity, although the drug has been shown to cause several different types of hepatotoxicity. The most striking reaction occurs when a chronic hepatitis develops that mimics chronic autoimmune hepatitis. Most patients who develop this condition are young people who have taken the medication for months without a problem.When a patient taking minocycline suddenly develops or is diagnosed with autoimmune hepatitis, a hepatologist should be consulted. The consultation is crucial, as both treatment and nontreatment can lead to further problems if not managed appropriately.

Lipid-lowering agents or statins (Lipitor, Zocor, Crestor).

Collectively called statins, this class of medications is used to treat elevated cholesterol and triglycerides. All statins work in similar ways, but the individual varieties may have differing degrees of potency. These medications have received extensive attention because they are widely used and have a propensity to cause elevations in liver enzymes (AST/ALT). It is estimated that 1 to 3 percent of patients taking statins will develop significantly elevated enzymes (greater than three times the upper limit of normal).

As the treatment guidelines for lowering cholesterol have become more aggressive over the past decade, the number of people taking these medications has increased substantially, leaving many clinicians (usually primary care providers) unclear about whether these medications should be used in patients with underlying liver disease and when to stop if liver enzymes become abnormal. These questions have not been fully answered, but statins seem extremely safe and should not be avoided by patients with underlying liver diseases if the statins are indicated for the treatment of high cholesterol or triglycerides. This is a clear case of the benefits outweighing the risks.

 

Information from other sources on Multaq Lawsuit:

Most patients who develop an increase in liver enzymes during therapy with statins will have only transient and mild elevation, which will resolve if the medication is stopped.

Ezetimibe (Zetia). This is another cholesterol-lowering medication, but it is not in the statin class of drugs. This medication inhibits the intestinal uptake of cholesterol and is often used with a statin when cholesterol cannot be lowered by a statin alone. In extremely rare cases, reports have connected it with drug-induced liver injury, but it is regarded as having an excellent safety profile. However, it is currently undergoing réévaluation of its effectiveness in preventing heart disease and stroke.

 

 

Our use of the term or terms Multaq Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq Lawsuit visit our site often.

http://www.seedol.com

Posted in Actos Litigation | Tagged , |

Multaq Lawsuit

By admin | Published January 3, 2012

Multaq Lawsuit : More than two dozen different blood tests are in current use to monitor specific liver functions and indicate disorders. That number does not include popular imaging studies, such as sonograms, CT scans, and MRIs. For patients, the landscape of liver testing resembles a confusing maze of high-tech jargon and initial-talk.

The liver is an unusually complex organ, responsible for filtering nearly every substance that comes into the body. As a result, it is vulnerable to a long list of potential hazards, from overloads of copper or iron to the hepatitis alphabet.

Many liver tests, such as the liver function tests sometimes referred to as a hepatic function panel (HFP), cannot accurately diagnose diseases because the disorders themselves have so many shared features. What liver function tests can do is to narrow the possibilities, advance the diagnostic procedures a step toward confirming the doctor s suspicions, and indicate which specialized tests the doctor and patient should undertake next.

 

More information on Multaq Lawsuit

Liver Function Tests (LFTs)

Liver function tests indicate how well the liver is performing particular functions and the levels of certain measurements associated with inflammation.

Dozens of different LFTs are performed in hospitals, but they all measure the levels of liver proteins, liver enzymes (called transaminases and cholestatic liver enzymes), and bilirubin.

 

Information from other sources on Multaq Lawsuit

Transamines: AST and ALT

Liver function tests that check the levels of aspartate transaminase (AST) and alanine transaminase (ALT) are looking for inflammation or injury to liver cells-—-in technical terms, hepatocellular liver injur)’’. When the liver is damaged, AST and ALT often leak into the bloodstream, so a blood test result that detected transamines would be a possible indicator of liver damage. However, AST is also found in the heart, kidneys, and muscles, so an elevated amount of AST doesn’t always mean a liver problem. When it is coupled with elevated ALT, which exists only in the liver, a higher AST level indicates that liver damage is more probable.

The extent of liver damage cannot be determined by high transaminase levels alone. If a patient drinks alcohol a few hours before the blood test or works out in the gym the morning his or her blood is drawn, the transaminase levels may be mildly elevated. On the other hand, if alcohol abuse damaged the liver five years ago, the transaminase level may be normal, but still there could be residual liver damage.

Moreover, men tend to have higher transaminase levels than women, and African American men usually show higher AST and ALT levels than Caucasian men. Almost everyone’s transaminase levels are higher in the morning than they are later in the day.

 

Our use of the term or terms Multaq Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq Lawsuit visit our site often.

http://www.seedol.com

Posted in Actos Litigation | Tagged , |

  • Contact Form

    Your Name (required)

    Your Email (required)

    Phone (required)

    Case Details

    Contact Form Agreement